Patents by Inventor Florian Colbatzky

Florian Colbatzky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
    Patent number: 8431585
    Abstract: The present invention relates to the use of specific EGF-receptor antagonists for preparing a pharmaceutical composition for the prevention and/or treatment of benign prostatic hyperplasia and/or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia/prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), described herein optionally in combination with known compounds for the treatment of benign prostatic hyperplasia/prostatic hypertrophy, as well as associated pharmaceutical compositions.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: April 30, 2013
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Thomas Singer, Stefan Platz, Florian Colbatzky
  • Dihydropteridinone compounds
    Patent number: 8003786
    Abstract: Disclosed are new dihydropteridinones of general formula (I) wherein the groups L and R1-R5 have the meanings given in the claims and specification, the isomers thereof, intermediates and processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: August 23, 2011
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Matthias Hoffmann, Matthias Grauert, Martin Steegmaier, Anke Baum, Jens Juergen Quant, Flavio Solca, Florian Colbatzky, Gisela Schnapp
  • Use of Lck inhibitors for treatment of immunologic diseases
    Patent number: 7989474
    Abstract: The invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using certain Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives, pharmaceutical compositions comprising said Lck inhibitors together with said other drugs, and the use of the Lck inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: August 2, 2011
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Gerald Juergen Roth, Armin Heckel, Rainer Walter, Frank Hilberg, Rudolf Hauptmann, Martin Fredrich Stefanic, Florian Colbatzky, Steffan Ernest
  • Dihydropteridinone Compounds
    Publication number: 20100324288
    Abstract: Disclosed are new dihydropteridinones of general formula (I) wherein the groups L and R1-R5 have the meanings given in the claims and specification, the isomers thereof, intermediates and processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.
    Type: Application
    Filed: September 1, 2010
    Publication date: December 23, 2010
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventors: Matthias HOFFMANN, Matthias GRAUERT, Martin STEEGMAIER, Gisela SCHNAPP, Anke BAUM, Jens Juergen QUANT, Flavio SOLCA, Florian COLBATZKY
  • Methods for treating diseases or conditions using dihydropteridinone compounds
    Patent number: 7786299
    Abstract: Disclosed are new dihydropteridinones of general formula (I) wherein the groups L and R1-R5 have the meanings given in the claims and specification, the isomers thereof, intermediates and processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.
    Type: Grant
    Filed: September 6, 2005
    Date of Patent: August 31, 2010
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Matthias Hoffmann, Matthias Grauert, Martin Steegmaier, Anke Baum, Jens Jurgen Quant, Flavio Solca, Florian Colbatzky
  • Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions and processes of making the same
    Patent number: 7750152
    Abstract: Disclosed are dihydropteridinones of general formula (I) wherein the groups L and R1-R5 have the meanings given in the claims and specification, the pharmaceutical compositions, isomers, intermediates thereof and processes for preparing these dihydropteridinones. The compounds are useful the treatment and/or prevention of cancer, infections, inflammatory and autoimmune diseases.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: July 6, 2010
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Matthias Hoffman, Matthias Grauert, Trixi Brandl, Steffen Breitfelder, Christian Eickmeier, Martin Steegmaier, Gisela Schnapp, Anke Baum, Jens Jurgen Quant, Flavio Solca, Florian Colbatzky
  • USE OF INHIBITORS OF THE EGFR-MEDIATED SIGNAL TRANSDUCTION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) / PROSTATIC HYPERTROPHY
    Publication number: 20100144639
    Abstract: The present invention relates to the use of specific EGF-receptor antagonists for preparing a pharmaceutical composition for the prevention and/or treatment of benign prostatic hyperplasia and/or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia/prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), described herein optionally in combination with known compounds for the treatment of benign prostatic hyperplasia/prostatic hypertrophy, as well as associated pharmaceutical compositions.
    Type: Application
    Filed: February 17, 2010
    Publication date: June 10, 2010
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventors: Thomas SINGER, Stefan PLATZ, Florian COLBATZKY
  • Use of Lck inhibitors for treatment of immunologic diseases
    Publication number: 20090306104
    Abstract: The invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using certain Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives, pharmaceutical compositions comprising said Lck inhibitors together with said other drugs, and the use of the Lck inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.
    Type: Application
    Filed: August 16, 2009
    Publication date: December 10, 2009
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventors: Gerald Juergen Roth, Armin Heckel, Rainer Walter, Frank Hilberg, Rudolf Hauptmann, Martin Fredrich Stefanic, Florian Colbatzky, Steffan Ernest
  • Use of Lck inhibitors for treatment of immunologic diseases
    Publication number: 20090087405
    Abstract: The invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using certain Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives, pharmaceutical compositions comprising said Lck inhibitors together with said other drugs, and the use of the Lck inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.
    Type: Application
    Filed: December 12, 2008
    Publication date: April 2, 2009
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Gerald Juergen ROTH, Armin HECKEL, Rainer WALTER, Frank HILBERG, Rudolf HAUPTMANN, Martin Friedrich STEFANIC, Florian COLBATZKY, Steffen ERNST
  • Piperazinyl Compounds
    Publication number: 20080293944
    Abstract: Disclosed are new dihydropteridinones of general formula (I) wherein the groups L and R1-R5 have the meanings given in the claims and specification, the isomers thereof, intermediates and processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.
    Type: Application
    Filed: May 30, 2008
    Publication date: November 27, 2008
    Inventors: Matthias Hoffmann, Matthias Grauert, Trixi Brandl, Steffen Breitfelder, Christian Eickmeier, Martin Steegmaier, Gisela Schnapp, Anke Baum, Jens Juergen Quant, Flavio Solca, Florian Colbatzky
  • Intermediate Compounds for making Dihydropteridinones Useful as Pharmaceutical Compositions
    Publication number: 20080171747
    Abstract: Disclosed are new dihydropteridinones of general formula (I) wherein the groups L and R1-R5 have the meanings given in the claims and specification, the isomers thereof, intermediates and processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.
    Type: Application
    Filed: November 16, 2007
    Publication date: July 17, 2008
    Inventors: Matthias Hoffman, Matthias Grauert, Trixi Brandl, Steffen Breitfelder, Christian Eickmeier, Martin Steegmaier, Gisela Schnapp, Anke Baum, Jens Juergen Quant, Flavio Solca, Florian Colbatzky
  • Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy
    Publication number: 20070099918
    Abstract: The present invention relates to the use of specific EGF-receptor antagonists for preparing a pharmaceutical composition for the prevention and/or treatment of benign prostatic hyperplasia and/or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia/prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), described herein optionally in combination with known compounds for the treatment of benign prostatic hyperplasia/prostatic hypertrophy, as well as associated pharmaceutical compositions.
    Type: Application
    Filed: December 12, 2006
    Publication date: May 3, 2007
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Thomas Singer, Stefan Platz, Florian Colbatzky
  • Prodrugs of 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amide
    Patent number: 7189743
    Abstract: The present invention relates to new compounds of general formula having thrombin-inhibiting activity. Exemplary are: 1-Methyl-2-[4-(N-hydroxyamidino)-phenylaminomethyl]-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-ethoxycarbonylethyl)-amide, and 1-Methyl-2-[4-(N-methoxycarbonylamidino)-phenylaminomethyl]-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amide.
    Type: Grant
    Filed: February 11, 2005
    Date of Patent: March 13, 2007
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Norbert Hauel, Florian Colbatzky, Ulrich Busch
  • Methods for treating diseases or conditions using dihydropteridinone compounds
    Publication number: 20060025411
    Abstract: Disclosed are new dihydropteridinones of general formula (I) wherein the groups L and R1-R5 have the meanings given in the claims and specification, the isomers thereof, intermediates and processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.
    Type: Application
    Filed: September 6, 2005
    Publication date: February 2, 2006
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Matthias Hoffmann, Matthias Grauert, Martin Steegmaier, Anke Baum, Jens Quant, Flavio Solca, Florian Colbatzky
  • Prodrugs of 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amide
    Publication number: 20050137233
    Abstract: The present invention relates to new compounds of general formula having thrombin-inhibiting activity. Exemplary are: 1-Methyl-2-[4-(N-hydroxyamidino)-phenylaminomethyl]-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-ethoxycarbonylethyl)-amide, and 1-Methyl-2-[4-(N-methoxycarbonylamidino)-phenylaminomethyl]-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amide.
    Type: Application
    Filed: February 11, 2005
    Publication date: June 23, 2005
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Norbert Hauel, Florian Colbatzky, Ulrich Busch
  • Prodrugs of 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amide
    Patent number: 6900229
    Abstract: The present invention relates to new compounds of general formula having thrombin-inhibiting activity. Exemplary are: 1-Methyl-2-[4-(N-hydroxyamidino)-phenylaminomethyl]-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-ethoxycarbonylethyl)-amide, and 1-Methyl-2-[4-(N-methoxycarbonylamidino)-phenylaminomethyl]-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amide.
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: May 31, 2005
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Norbert Hauel, Florian Colbatzky, Ulrich Busch
  • Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
    Patent number: 6861422
    Abstract: The present invention relates to new dihydropteridinones of general formula (I): wherein the groups L and R1-R5 have the meanings given in the claims and specification, the isomers thereof, processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.
    Type: Grant
    Filed: February 26, 2003
    Date of Patent: March 1, 2005
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Matthias Hoffmann, Matthias Grauert, Trixi Brandl, Steffen Breitfelder, Christian Eickmeier, Martin Steegmaier, Gisela Schnapp, Anke Baum, Jens Juergen Quant, Flavio Solca, Florian Colbatzky
  • Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions
    Publication number: 20050014761
    Abstract: Disclosed are new dihydropteridinones of general formula (I) wherein the groups L and R1-R5 have the meanings given in the claims and specification, the isomers thereof, intermediates and processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.
    Type: Application
    Filed: July 30, 2004
    Publication date: January 20, 2005
    Inventors: Matthias Hoffmann, Matthias Grauert, Trixi Brandl, Steffen Breitfelder, Christian Eickmeier, Martin Steegmaier, Gisela Schnapp, Anke Baum, Jens Quant, Flavio Solca, Florian Colbatzky
  • Methods of treating diseases or conditions using dihydropteridinone compounds
    Publication number: 20050014760
    Abstract: Disclosed are new dihydropteridinones of general formula (I) wherein the groups L and R1-R5 have the meanings given in the claims and specification, the isomers thereof, intermediates and processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.
    Type: Application
    Filed: July 30, 2004
    Publication date: January 20, 2005
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Matthias Hoffmann, Matthias Grauert, Trixi Brandl, Steffen Breitfelder, Christian Eickmeier, Martin Steegmaier, Gisela Schnapp, Anke Baum, Jens Quant, Flavio Solca, Florian Colbatzky
  • Use of Lck inhibitors for treatment of immunologic diseases
    Publication number: 20040204458
    Abstract: The invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using certain Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives, pharmaceutical compositions comprising said Lck inhibitors together with said other drugs, and the use of the Lck inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.
    Type: Application
    Filed: August 14, 2003
    Publication date: October 14, 2004
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Gerald Juergen Roth, Armin Heckel, Rainer Walter, Frank Hilberg, Rudolf Hauptmann, Martin Friedrich Stefanic, Florian Colbatzky, Steffen Ernst